Targeting Oncogenic Gene Fusions in Lung Cancer.

Authors

Yunan Nie, Frederick H Wilson

Published in

Cancer journal (Sudbury, Mass.). Volume 32. Issue 4. Epub Jul 24, 2026.

Abstract

Oncogenic gene fusions define a clinically important subset of non-small cell lung carcinoma (NSCLC) for which targeted therapies have transformed outcomes. Over the past 15 years, successive generations of tyrosine kinase inhibitors (and more recently, monoclonal antibodies) have demonstrated substantial improvements in response rates, progression-free survival, and central nervous system control across multiple fusion-defined populations. This review consolidates current evidence for FDA-approved therapies targeting ALK, ROS1, RET, NTRK, and NRG1 fusions in lung cancer, highlighting mechanisms of action, pivotal clinical trials, resistance patterns, and toxicity profiles. We also discuss advances in molecular diagnostics (including the growing role of RNA-based sequencing) and emerging strategies in the adjuvant and perioperative settings. Finally, we outline ongoing clinical trials and future directions aimed at overcoming resistance and expanding precision oncology approaches for patients with rare fusion-driven lung cancers.

PMID:
42497393
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.